PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+20.77%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$707M
AUM Growth
+$707M
(+30%)
Cap. Flow
+$87.9M
Cap. Flow
% of AUM
12.44%
Top 10 Holdings %
Top 10 Hldgs %
36.4%
Holding
113
New
10
Increased
54
Reduced
24
Closed
24
Top Buys
| 1 |
Abbott
ABT
|
$17.3M |
| 2 |
Inspire Medical Systems
INSP
|
$15.6M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$13.3M |
| 4 |
Amgen
AMGN
|
$12M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$11.4M |
Top Sells
| 1 |
HCA Healthcare
HCA
|
$13.8M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$11.4M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$8.68M |
| 4 |
Charles River Laboratories
CRL
|
$8.65M |
| 5 |
Zimmer Biomet
ZBH
|
$7.97M |
Sector Composition
| 1 | Healthcare | 99.16% |
| 2 | Industrials | 0.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Boston Scientific
BSX
$156B
| $37.7M | 5.32% | 652,803 +55,543 | +9% | +$3.21M |
|
2
United Therapeutics
UTHR
$13.8B
| $35.5M | 5% | 161,539 +23,211 | +17% | +$5.1M |
|
3
Cooper Companies
COO
$13.4B
| $28.5M | 4.01% | 75,183 +9,862 | +15% | +$3.73M |
|
4
DexCom
DXCM
$29.5B
| $28M | 3.94% | 225,615 -39,903 | -15% | -$4.95M |
|
5
Tenet Healthcare
THC
$16.3B
| $27M | 3.8% | 356,806 +130,665 | +58% | +$9.87M |
|
6
Cencora
COR
$56.5B
| $21.1M | 2.98% | 102,891 +6,046 | +6% | +$1.24M |
|
|
7
Inspire Medical Systems
INSP
$2.77B
| $21.1M | 2.97% | 103,746 +76,823 | +285% | +$15.6M |
|
8
RxSight
RXST
$370M
| $20.7M | 2.91% | 513,032 +131,701 | +35% | +$5.31M |
|
9
Insulet
PODD
$23.9B
| $19.2M | 2.71% | 88,675 +46,650 | +111% | +$10.1M |
|
10
Neurocrine Biosciences
NBIX
$13.8B
| $18.5M | 2.6% | 140,116 +56,271 | +67% | +$7.41M |
|
|
11
Amgen
AMGN
$155B
| $17.7M | 2.5% | 61,524 +41,524 | +208% | +$12M |
|
|
12
Abbott
ABT
$231B
| $17.3M | 2.43% | +156,727 | New | +$17.3M |
|
13
Vaxcyte
PCVX
$4B
| $16.8M | 2.37% | 267,594 +29,462 | +12% | +$1.85M |
|
14
Becton Dickinson
BDX
$55.3B
| $16.4M | 2.32% | 67,458 -30,494 | -31% | -$7.44M |
|
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $16M | 2.25% | 738,589 +526,141 | +248% | +$11.4M |
|
16
Schrodinger
SDGR
$1.44B
| $14.5M | 2.04% | 405,232 +36,578 | +10% | +$1.31M |
|
17
Keros Therapeutics
KROS
$618M
| $14.3M | 2.02% | 360,467 +61,992 | +21% | +$2.46M |
|
18
Xenon Pharmaceuticals
XENE
$2.98B
| $13.6M | 1.91% | 294,788 +78,144 | +36% | +$3.6M |
|
|
ITCI
19
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $13.3M | 1.88% | +186,272 | New | +$13.3M |
|
20
Qiagen
QGEN
$10.1B
| $10.9M | 1.53% | +250,000 | New | +$10.9M |
|
21
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $10.8M | 1.52% | 615,693 +105,883 | +21% | +$1.86M |
|
22
Ionis Pharmaceuticals
IONS
$6.79B
| $10.7M | 1.51% | 211,400 +51,897 | +33% | +$2.63M |
|
|
VRNA
23
Verona Pharma
VRNA
$9.16B
| $10M | 1.41% | 504,742 +86,809 | +21% | +$1.73M |
|
24
Arcellx
ACLX
$3.85B
| $9.34M | 1.32% | 168,262 -35,220 | -17% | -$1.95M |
|
25
Travere Therapeutics
TVTX
$1.56B
| $9.16M | 1.29% | 1,018,812 +441,318 | +76% | +$3.97M |
|